Published in Br J Clin Pharmacol on March 01, 1979
Decreased clearance of diflunisal in renal insufficiency--an alternative explanation. Br J Clin Pharmacol (1980) 1.06
Decreased body clearance of diflunisal in renal insufficiency--an alternative explanation. Br J Clin Pharmacol (1979) 1.04
Pharmacokinetics of carumonam in patients with renal insufficiency. Antimicrob Agents Chemother (1986) 1.01
Pharmacokinetics of intravenous cefetamet and oral cefetamet pivoxil in patients with renal insufficiency. Antimicrob Agents Chemother (1989) 0.91
Effect of food and various antacids on the absorption of tenoxicam. Br J Clin Pharmacol (1987) 0.88
Effect of dose on the glucuronidation and sulphation kinetics of diflunisal in man: single dose studies. Br J Clin Pharmacol (1988) 0.86
The effect of multiple dosage on the kinetics of glucuronidation and sulphation of diflunisal in man. Br J Clin Pharmacol (1990) 0.83
Effect of aluminum hydroxide on diflunisal absorption. Br J Clin Pharmacol (1979) 0.81
Diflunisal and its conjugates in patients with renal failure. Br J Clin Pharmacol (1991) 0.80
The influence of diflunisal on the pharmacokinetics of oxazepam. Br J Clin Pharmacol (1985) 0.80
Reduced elimination of ketoprofen in the elderly is not necessarily due to impaired glucuronidation. Br J Clin Pharmacol (1984) 0.80
Impaired elimination of lorazepam following subchronic administration in two patients with renal failure. Br J Clin Pharmacol (1981) 0.76
Pharmacokinetic profile of indoprofen in elderly subjects. Br J Clin Pharmacol (1986) 0.75
Non-steroidal Anti-inflammatory Drugs: Monitoring to help prevent serious adverse effects. Can Fam Physician (1991) 0.75
Physiological disposition and metabolism of 5-(2',4'-difluorophenyl)salicyclic acid, a new salicylate. Drug Metab Dispos (1976) 2.23
Limited capacity for salicyl phenolic glucuronide formation and its effect on the kinetics of salicylate elimination in man. Clin Pharmacol Ther (1972) 1.90
The biotransformation of drugs in renal failure. Am J Med (1977) 1.70
Persistence of antibiotics in blood of patients with acute renal failure. II. Chloramphenicol and its metabolic products in the blood of patients with severe renal disease or hepatic cirrhosis. J Clin Invest (1959) 1.68
Drug biotransformation interactions in man. I. Mutual inhibition in glucuronide formation of salicylic acid and salicylamide in man. J Pharm Sci (1968) 1.29
Drug kinetics and artificial kidneys. Clin Pharmacokinet (1978) 1.23
Diflunisal: efficacy in postoperative pain. Br J Clin Pharmacol (1977) 1.18
The effect of end-stage renal failure and haemodialysis on the elimination kinetics of sotalol. Br J Clin Pharmacol (1976) 1.12
Pharmacokinetics of acetaminophen elimination by anephric patients. J Pharmacol Exp Ther (1976) 1.09
Individualization of drug dosage in patients with renal disease. Med Clin North Am (1974) 1.05
A guide to drug therapy in renal failure. JAMA (1974) 1.01
Drug administration in renal failure. Am J Med (1977) 0.94
In vitro activity and human pharmacokinetics of teicoplanin. Antimicrob Agents Chemother (1984) 3.66
Piperacillin: human pharmacokinetics after intravenous and intramuscular administration. Antimicrob Agents Chemother (1978) 2.95
Quality and efficiency of bystander CPR. Belgian Cerebral Resuscitation Study Group. Resuscitation (1993) 1.80
Restoration of spontaneous circulation after cessation of cardiopulmonary resuscitation. Lancet (1993) 1.47
Survival after out-of-hospital cardiac arrest in elderly patients. Belgian Cerebral Resuscitation Study Group. Ann Emerg Med (1992) 1.43
Developmental pharmacology: neonates are not just small adults... Acta Clin Belg (2008) 1.36
Comparative pharmacokinetics of ceftazidime and moxalactam. Antimicrob Agents Chemother (1982) 1.33
Acute bronchodilation with an intravenously administered leukotriene D4 antagonist, MK-679. Am Rev Respir Dis (1993) 1.15
Pharmacokinetics of a loading dose of intravenous paracetamol post caesarean delivery. Int J Obstet Anesth (2012) 1.14
The effect of end-stage renal failure and haemodialysis on the elimination kinetics of sotalol. Br J Clin Pharmacol (1976) 1.12
The clinical significance of error measurement in the interpretation of treatment results. Eur J Orthod (2001) 1.08
Tolerance and pharmacokinetics of propacetamol, a paracetamol formulation for intravenous use. Fundam Clin Pharmacol (1992) 1.07
Ranitidine: single dose pharmacokinetics and absolute bioavailability in man. Br J Clin Pharmacol (1982) 1.02
Bartter's syndrome with hyperplasia of renomedullary cells: successful treatment with indomethacin. Kidney Int (1976) 1.01
Focal xanthogranulomatous pyelonephritis mimicking a renal tumor: CT- and MR-findings and evolution under therapy. Nephrol Dial Transplant (1997) 0.99
The effect of rofecoxib on the pharmacodynamics and pharmcokinetics of warfarin. Clin Pharmacol Ther (2000) 0.98
Mezlocillin pharmacokinetics. Comparison with ampicillin and influence of probenecid. Arzneimittelforschung (1979) 0.97
Inter-individual variability in propofol pharmacokinetics in preterm and term neonates. Br J Anaesth (2007) 0.97
The effect of tooth size discrepancy on occlusion: An experimental study. Am J Orthod Dentofacial Orthop (2000) 0.97
Comparative pharmacokinetics of piperacillin in normals and in patients with renal failure. J Antimicrob Chemother (1982) 0.95
Sex proportions of Haemoproteus blood parasites and local mate competition. Proc Natl Acad Sci U S A (1995) 0.95
[Histological course of diffuse proliferative glomerulonephritis treated with indomethacin]. J Urol Nephrol (Paris) (1970) 0.95
Voriconazole plasma levels in children are highly variable. Eur J Clin Microbiol Infect Dis (2010) 0.94
Clinical feasibility trials of barbiturate therapy after cardiac arrest. Crit Care Med (1978) 0.91
Influence of the hemodialysis on the half-life of practolol in patients with severe renal failure. J Clin Pharmacol (1975) 0.90
Increase in antioxidant capacity of plasma during propofol anesthesia. J Neurosurg Anesthesiol (1997) 0.89
Biotransformation and excretion of lorazepam in patients with chronic renal failure. Br J Clin Pharmacol (1976) 0.89
Comparative oral pharmacokinetics of fleroxacin and pefloxacin. J Antimicrob Chemother (1988) 0.87
Pharmacokinetics of intravenous ketorolac following caesarean delivery. Int J Obstet Anesth (2012) 0.87
Tramadol disposition in the very young: an attempt to assess in vivo cytochrome P-450 2D6 activity. Br J Anaesth (2005) 0.87
Plasma-fluphenazine concentrations after injection of long-acting esters. Lancet (1978) 0.86
Block of volume-regulated anion channels by selective serotonin reuptake inhibitors. Naunyn Schmiedebergs Arch Pharmacol (2002) 0.85
Efficacy and tolerance of treatment with recombinant-human erythropoietin in chronic renal failure (pre-dialysis) patients. Nephrol Dial Transplant (1989) 0.85
The tibialis tendon as a valuable anterior cruciate ligament allograft substitute: biomechanical properties. Knee Surg Sports Traumatol Arthrosc (2007) 0.84
Primary sclerosing cholangitis associated with membranous nephropathy. Ann Intern Med (1988) 0.84
O-demethylation of tramadol in the first months of life. Eur J Clin Pharmacol (2005) 0.84
Disappearance of vascular calcifications during treatment of renal osteodystrophy. Two patients treated with high doses of vitamin D and aluminum hydroxide. Ann Intern Med (1975) 0.84
Cerebrospinal fluid pharmacokinetics of paracetamol after intravenous propacetamol in a former preterm infant. Br J Clin Pharmacol (2004) 0.83
Decision making to cease or to continue cardiopulmonary resuscitation (CPR). The Cerebral Resuscitation Study Group. Resuscitation (1989) 0.83
Osteodystrophy of dialysed patients treated with vitamin D. Proc Eur Dial Transplant Assoc (1973) 0.83
Reversal of hepatorenal syndrome in four patients by peroral misoprostol (prostaglandin E1 analogue) and albumin administration. J Hepatol (1990) 0.83
Longitudinal follow-up of TTS-fentanyl use in patients with cancer-related pain: results of a compassionate-use study with special focus on elderly patients. Curr Med Res Opin (2002) 0.83
Observations on the disposition of probenecid in patients receiving allopurinol. Pharmacology (1972) 0.83
Altered pharmacokinetics of oral flecainide by cimetidine. Br J Clin Pharmacol (1986) 0.82
Kinetics of fluphenazine after fluphenazine dihydrochloride, enanthate and decanoate administration to man. Br J Clin Pharmacol (1979) 0.82
An audit of in-hospital crash team interventions outside critical care areas. Eur J Emerg Med (1996) 0.82
Transplacental transfer of anthracyclines, vinblastine, and 4-hydroxy-cyclophosphamide in a baboon model. Gynecol Oncol (2010) 0.82
Chemolysis of calcium containing urinary calculi. A review. Acta Urol Belg (1994) 0.82
Clinical evaluation of cephaloglycin in the treatment of urinary tract infections. Chemotherapy (1968) 0.82
Symptomatic hypoglycemia in a patient with chronic hemodialysis. Acta Clin Belg (2007) 0.81
Effect of aluminum hydroxide on diflunisal absorption. Br J Clin Pharmacol (1979) 0.81
Influence on outcome after cardiac arrest of time elapsed between call for help and start of bystander basic CPR. The Belgian Cerebral Resuscitation Study Group. Resuscitation (1993) 0.81
Urinary metabolites to assess in vivo ontogeny of hepatic drug metabolism in early neonatal life. Methods Find Exp Clin Pharmacol (2007) 0.81
Pharmacokinetics and pharmacodynamics of multiple oral doses of MK-0591, a 5-lipoxygenase-activating protein inhibitor. Clin Pharmacol Ther (1994) 0.80
The influence of diflunisal on the pharmacokinetics of oxazepam. Br J Clin Pharmacol (1985) 0.80
A near-fatal case of puerperal sepsis. Anaesth Intensive Care (1991) 0.80
Effect of montelukast on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. J Clin Pharmacol (1999) 0.80
High-performance liquid chromatographic determination of 12 antiarrhythmic drugs in plasma using solid-phase column extraction. Ther Drug Monit (1991) 0.79
Early prediction of non-survival for patients suffering cardiac arrest--a word of caution. The Belgian Cerebral Resuscitation Study Group. Intensive Care Med (1992) 0.79
Effect of rofecoxib on the pharmacokinetics of digoxin in healthy volunteers. J Clin Pharmacol (2001) 0.79
Contribution of glucuronidation to tramadol disposition in early neonatal life. Basic Clin Pharmacol Toxicol (2006) 0.79
Lack of interaction between famotidine and warfarin. Int J Clin Pharmacol Res (1990) 0.79
Dantrolene is neuroprotective in vitro, but does not affect survival in SOD1(G⁹³A) mice. Neuroscience (2012) 0.79
Gastrointestinal blood loss after diflunisal and after aspirin: effect of ethanol. Clin Pharmacol Ther (1978) 0.79
Dental wear in horses in relation to the microhardness of enamel and dentine. Vet Rec (1999) 0.79
Cefazolin plasma protein binding and its covariates in neonates. Eur J Clin Microbiol Infect Dis (2012) 0.79
Relative bioavailability of enteric coated pellets, stearate and ethylsuccinate formulations of erythromycin. Pharmacology (1984) 0.78
Evaluation of succinimidoethyl and pivaloyloxyethyl esters as progenitors of methyldopa in man, rhesus monkey, dog, and rat. Drug Metab Dispos (1979) 0.78
Effect of antacids on the bioavailability of diflunisal in the fasting and postprandial states. Clin Pharmacol Ther (1981) 0.78
The addition of calcium ions to starch/Carbopol mixtures enhances the nasal bioavailability of insulin. Eur J Pharm Biopharm (2007) 0.78
Influence of dialysate calcium concentration and vitamin D on serum parathyroid hormone during repetitive dialysis. Kidney Int (1975) 0.78
Effect of hemodialysis on plasma kinetics of fenofibrate in chronic renal failure. Nephron (1982) 0.78
Monitoring of cerebrospinal fluid enzyme levels in postischemic encephalopathy after cardiac arrest. Crit Care Med (1981) 0.78